Which hormone binds to the receptor site on the surface of a target cell?

Membrane-associated receptor proteins usually consist of extracellular sequences that recognize and bind ligand, transmembrane-anchoring hydrophobic sequences, and intracellular sequences, which initiate intracellular signaling. Intracellular signaling is mediated by covalent modification and activation of intracellular signaling molecules (e.g., signal transducers and activators of transcription [STAT] proteins) or by generation of small molecule second messengers (e.g., cyclic adenosine monophosphate) through activation of heterotrimeric G proteins. Subunits of these G proteins (α-subunits, β-subunits, and γ-subunits) activate or suppress effector enzymes and ion channels that generate the second messengers. Some of these receptors (e.g., those for somatostatin) may in fact exhibit low constitutive activity and have been shown to signal in the absence of added ligand.

Several growth factors and hormone receptors (e.g., for insulin) behave as intrinsic tyrosine kinases or activate intracellular protein tyrosine kinases. Ligand activation may cause receptor dimerization (e.g., GH) or heterodimerization (e.g., interleukin 6), followed by activation of intracellular phosphorylation cascades. These activated proteins ultimately determine specific nuclear gene expression.

Both the number of receptors expressed per cell and their responses are regulated, thus providing a further level of control for hormone action. Several mechanisms account for altered receptor function. Receptor endocytosis causes internalization of cell surface receptors; the hormone-receptor complex is subsequently dissociated, resulting in abrogation of the hormone signal. Receptor trafficking may then result in recycling back to the cell surface (e.g., as for the insulin receptor) or the internalized receptor may undergo lysosomal degradation. Both these mechanisms triggered by activation of receptors effectively lead to impaired hormone signaling downregulation of the receptors. The hormone signaling pathway may also be downregulated by receptor desensitization (e.g., as for epinephrine); ligand-mediated receptor phosphorylation leads to a reversible deactivation of the receptor. Desensitization mechanisms can be activated by a receptor’s ligand (homologous desensitization) or by another signal (heterologous desensitization), thereby attenuating receptor signaling in the continued presence of ligand. Receptor function may also be limited by action of specific phosphatases (e.g., Src homology phosphatase [SHP]) or by intracellular negative regulation of the signaling cascade (e.g., suppressor of cytokine signaling [SOCS] proteins inhibiting Janus kinase/signal transducers and activators of transcription [JAK-STAT] signaling). Certain ligand-receptor complexes may also translocate to the nucleus.

View chapter on ClinicalKey

Endocrine Glands

Jahangir Moini, ... Raheleh Ahangari, in Epidemiology of Endocrine Tumors, 2020

Control of target cell hormones

Target cell sensitivity to a certain hormone is partly based on the amount of receptors for that hormone that the target cell has. The more receptors, the higher the target cell’s sensitivity. Hormone receptors are continuously broken down and replaced. This ensures that all parts of the cell are new and functioning correctly, and also allows numbers of receptors to be altered as needed. When new receptor synthesis occurs faster than old receptor degradation, the target cell becomes more sensitive to a hormone. This is often referred to as up-regulation since the number of receptors increases (see Fig. 1.7). When the opposite occurs, it is called down-regulation.

Which hormone binds to the receptor site on the surface of a target cell?

Fig. 1.7. The (A) up-regulation and (B) down-regulation of target cell sensitivity.

Endocrine system diseases may be quite varied, with many different outcomes, some of which are highly significant. Endocrine tumors are an example of a disease that can cause endocrine hormone hypersecretion or hyposecretion. Other outcomes that are related to these changes in secretion include diabetes mellitus and polyendocrine disorders.

View chapterPurchase book

Read full chapter

URL: https://www.sciencedirect.com/science/article/pii/B9780128221877000141

Immunology of Infection

Patricia Graef, ... Dirk H. Busch, in Methods in Microbiology, 2010

6 Limitations of direct CTL assays

Using target cells infected with intracellular pathogens as CTL targets has certain disadvantages that can limit the utility of these assays. For example, the pathogen will continue to multiply inside the infected target cells. Pathogens with a high intracellular growth rate might simply burst the infected cell within a relatively short time period, resulting in a rapid increase of spontaneous 51Cr-release. Alternatively, some intracellular pathogens release lytic proteins that can cause high degrees of spontaneous lysis in the absence of CTL. If the spontaneous release of 51Cr exceeds 30–40% of maximum release values, then the specific lysis values become very difficult to interpret.

Although the incubation time for CTL assays can be shortened to prevent exceedingly high spontaneous release values, there is a certain delay until specific target cell lysis is detectable; a minimum incubation time of 2–3 h is needed. Possible explanations for the delayed onset of specific lysis are that specific CTLs need time to find their target cells and to induce cell death, and that target cells may not immediately release all 51Cr upon encounter with a specific CTL.

View chapterPurchase book

Read full chapter

URL: https://www.sciencedirect.com/science/article/pii/S0580951710370085

Apoptosis

Lianfa Shi, ... Arnold H. Greenberg, in Methods in Enzymology, 2000

A. 51Cr Release Assay

Target cells are labeled by incubating 100 μCi of labeled sodium chromate (51CrNa2CrO4; Amersham, Arlington Heights, IL) with 2 × 106 cells in 0.5 ml of RPMI 1640–10% (v/v) FCS at 37° for 1 hr. Lymphoid target cells such as YAC-1, Jurkat, etc., are good targets for this assay. The labeled cells are washed three times with cold HBSS and resuspended in HH–BSA (see Section VI,A below) at 1 × 105 cells/ml. Perforin isolated by FPLC usually contains a high concentration of NaCl and should be diluted to 0.145 M NaCl with HE before use, then further diluted with HE-Na for a perforin titration. The assay is easily performed in a 96-well V-bottom microplate. An aliquot of 100 μl containing 1 × 104 target cells is added to 100 μl of diluted perforin. Several disposable test tubes, each with 100 μl of cells, are set aside to measure the total 51Cr label added to each well. After 1 hr of incubation in a CO2 incubator at 37°, the plate is centrifuged at 400g for 5 min. A 100-μl aliquot of supernatant from each well is carefully removed and placed in tubes to be counted in a γ scintillation counter. The percentage (%) of specific 51Cr release is calculated by doubling the counts in the supernatant to adjust for volume and then dividing by the total label added to each well.

View chapterPurchase book

Read full chapter

URL: https://www.sciencedirect.com/science/article/pii/S0076687900220132

Immunotherapy

Anahid Jewett, Han-Ching Tseng, in Pharmacology and Therapeutics for Dentistry (Seventh Edition), 2017

Cytolytic activities

A target cell may become resistant to apoptotic signaling mediated by the aforementioned surface ligands, especially if the cell is infected by a virus that produces apoptotic inhibitors. In this case, NK cells and the cytotoxic T lymphocytes must depend on cytolytic factors to kill the damaged cell. Within the vesicular components and dense cores of these granules are numerous potentially cytocidal proteins. The vesicles and dense cores are discharged when the cytotoxic granules fuse with the plasma membrane of the NK cell or cytotoxic T lymphocyte.

Granule exocytosis can provide additional death-inducing factors. One factor is perforin. Perforin can form polymeric channels in cell membranes. Affected membranes lose their structural integrity, and lysis of the cell soon follows. The second factor is granzyme B. Granzymes may gain access to the target cell, either directly by fusion of the granule vesicles or dense core with the membrane of the target cell or because of a sub-lytic quantity of perforin that allows granzymes to gain access to the cytosol of the target cell. When in the cytosol, granzyme B can activate apoptotic proteolysis.